Histamine Hl-receptor antagonist

Introduction Histamine receptors Histamine Hl-receptor antagonists H 2-receptor antagonists INTRODUCTION... 

Recently a number of pharmaceutical drugs have been withdrawn from the market or not granted approval due to their pro-arrhythmic tendencies linked to inhibition of hERG. Two examples of this are terfenadine (Seldane) [91], a histamine Hl-receptor antagonist, and cisapride (Propulsid) [92], a gastric pro-kinetic. For this reason the safety assessment profile of any novel compound must now consider the IC50 value of the compound for hERG. 

Honig P, Baraniuk JN. Adverse effects of Hl-receptor antagonists in the cardiovascular system. In Simons FER, editor. Histamine and Hl-receptor Antagonists in Allergic Disease. New York Marcel Dekker Inc, 1996 383 12. 

Brookhuis KA, De Vries G, De Waard D. Acute and subchronic effects of the Hl-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance. Br J Clin Pharmacol 1993 36 67-70. 

Nicholson AN, Stone BM. Performance studies with the Hl-histamine receptor antagonists, astemizole and ter-fenadine. Br J Chn Pharmacol 1982 13(2) 199-202. 

Seifert, R., Hoer, A., Schwaner, I., Buschauer, A. (1992). Histamine increases cytosolic Ca2+ in HL-60 promyelocytes predominantly via H2 receptors with an unique agonist/ antagonist profile and induces functional differentiation. Am. Soc. Pharmacol. Exp. Therapeut. 42,235-41. 

---